Epidemiologic, genetic, pathogenic, metabolic, epigenetic aspects involved in NASH-HCC: current therapeutic strategies

J Gutiérrez-Cuevas, S Lucano-Landeros… - Cancers, 2022 - mdpi.com
Simple Summary Hepatocellular carcinoma (HCC) is an aggressive human cancer and is
caused as consequences of chronic liver diseases. Although HCC is more common in …

Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition

S Tao, S Liang, T Zeng, D Yin - Frontiers in Immunology, 2023 - frontiersin.org
Hepatocellular carcinoma (HCC) constitutes most primary liver cancers and is one of the
most lethal and life-threatening malignancies globally. Unfortunately, a substantial …

Circulating miR-122-5p, miR-92a-3p, and miR-18a-5p as potential biomarkers in human liver transplantation follow-Up

C Morsiani, S Collura, F Sevini, E Ciurca… - International Journal of …, 2023 - mdpi.com
The requirement of blood-circulating sensitive biomarkers for monitoring liver transplant (LT)
is currently a necessary step aiming at the reduction of standard invasive protocols, such as …

Epigenetic remodelling in human hepatocellular carcinoma

MR Braghini, O Lo Re, I Romito… - Journal of Experimental …, 2022 - Springer
Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer, being the sixth
most commonly diagnosed cancer and the fourth leading cause of cancer-related death. As …

Construction of a Myc-associated ceRNA network reveals a prognostic signature in hepatocellular carcinoma

DD Zhang, Y Shi, JB Liu, XL Yang, R Xin… - … Therapy-Nucleic Acids, 2021 - cell.com
Hepatocellular carcinoma (HCC) remains an extremely lethal disease worldwide. High-
throughput methods have revealed global transcriptome dysregulation; however, a …

Activating transcription factor 2 promotes the progression of hepatocellular carcinoma by inducing the activation of the WHSC1‐mediated TOP2A/PI3K/AKT axis

ZM Bao, D Yao, X Qian, HG Zhang… - … Journal of Medical …, 2022 - Wiley Online Library
Abstract Activating transcription factor 2 (ATF2) is a tumor driver gene implicated in several
human malignancies. This study aimed to determine the roles of ATF2 and its related …

[HTML][HTML] Loss-of-function mutations of microRNA-142-3p promote ASH1L expression to induce immune evasion and hepatocellular carcinoma progression

XH Yu, Y Xie, J Yu, KN Zhang, ZB Guo… - World Journal of …, 2025 - pmc.ncbi.nlm.nih.gov
BACKGROUND Hepatocellular carcinoma (HCC) has been a pervasive malignancy
throughout the world with elevated mortality. Efficient therapeutic targets are beneficial to …

Cross talk between genetics and biochemistry in the pathogenesis of hepatocellular carcinoma

M Ucdal, A Burus, B Celtikci - Hepatology forum, 2024 - pmc.ncbi.nlm.nih.gov
The liver is a crucial organ in the regulation of metabolism, signaling, and homeostasis.
Using recent advanced sequencing technologies, several mutations of genes in major …

Lysine demethylase 5C epigenetically reduces transcription of ITIH1 that results in augmented progression of liver hepatocellular carcinoma

X Qian, ZM Bao, D Yao, Y Shi - The Kaohsiung Journal of …, 2022 - Wiley Online Library
Abstract Lysine demethylase 5C (KDM5C) is a member of the KDM family of demethylases
and has been reported as a cancer driver. This study aimed to probe the function of KDM5C …

Increase of ASH1L Expression Promotes Hepatocellular Carcinoma Development and Affects the Prognosis of Liver Transplantation Patients

X Yu, W Zhang, W Xiang, Y Ma, S Liu, Z Li, Y Tan, Y Xie… - 2023 - researchsquare.com
Hepatocellular carcinoma (HCC) is a prevalent malignancy worldwide, characterized by
high morbidity and mortality rates. Risk factors associated with HCC include cirrhosis …